Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioCryst’s Oral Therapy For HAE Attacks On Track With Exploratory Phase II Success

Executive Summary

Biocryst’s oral kallikrein inhibitor BCX7353 – already in Phase III for prophylaxis of hereditary angioedema – shows efficacy in a range of endpoints in a Phase II exploratory trial.

You may also be interested in...



Mixed Responses To BioCryst's Oral Phase III HAI Therapy, BCX7353

BioCryst’s BCX7353 could be the first oral therapy to prevent hereditary angioedema attacks, but it might not work in all patients, according to data from the Phase III APeX-2 study.

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123791

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel